Prediction of chemo-response in serous ovarian cancer

• Published in: Molecular cancer 2016-10, Vol.15 (1), p.66-66, Article 66
• Main Authors: Gonzalez Bosquet, Jesus, Newtson, Andreea M, Chung, Rebecca K, Thiel, Kristina W, Ginader, Timothy, Goodheart, Michael J, Leslie, Kimberly K, Smith, Brian J
• Format: Article
• Language: English
• Subjects: Analysis; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Area Under Curve; Cancer therapies; Care and treatment; Chemotherapy; Cystadenocarcinoma, Serous - drug therapy; Cystadenocarcinoma, Serous - genetics; Data collection; Datasets; Discriminant analysis; DNA methylation; Drug therapy; Female; Gene expression; Gene Expression Profiling - methods; Gene Expression Regulation, Neoplastic - drug effects; Gene Regulatory Networks - drug effects; Genetic aspects; Genomes; Humans; Medical prognosis; Methods; Middle Aged; Models, Genetic; Mortality; Oligonucleotide Array Sequence Analysis - methods; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - genetics; Precision Medicine; Prognosis; Surgery; Survival Analysis; Treatment Outcome; Variables
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/s12943-016-0548-9

Nearly one-third of serous ovarian cancer (OVCA) patients will not respond to initial treatment with surgery and chemotherapy and die within one year of diagnosis. If patients who are unlikely to respond to current standard therapy can be identified up front, enhanced tumor analyses and treatment regimens could potentially be offered. Using the Cancer Genome Atlas (TCGA) serous OVCA database, we previously identified a robust molecular signature of 422-genes associated with chemo-response. Our objective was to test whether this signature is an accurate and sensitive predictor of chemo-response in serous OVCA. We first constructed prediction models to predict chemo-response using our previously described 422-gene signature that was associated with response to treatment in serous OVCA. Performance of all prediction models were measured with area under the curves (AUCs, a measure of the model's accuracy) and their respective confidence intervals (CIs). To optimize the prediction process, we determined which elements of the signature most contributed to chemo-response prediction. All prediction models were replicated and validated using six publicly available independent gene expression datasets. The 422-gene signature prediction models predicted chemo-response with AUCs of ~70 %. Optimization of prediction models identified the 34 most important genes in chemo-response prediction. These 34-gene models had improved performance, with AUCs approaching 80 %. Both 422-gene and 34-gene prediction models were replicated and validated in six independent datasets. These prediction models serve as the foundation for the future development and implementation of a diagnostic tool to predict response to chemotherapy for serous OVCA patients.